Jaguar Animal Health, Inc. (NASDAQ:JAGX) Q1 2020 Earnings Conference Call - Preliminary Transcript
May 15, 2020 • 08:30 am ET
Thank you for standing by. This the conference operator. Welcome to the Jaguar Health Investor Conference Call. Before I turn the call over to management, I'd like to remind you that management may make forward-looking statements relating to such matters as continued growth prospects for the company, uncertainties regarding market acceptance of products, the impacts of competitive products and pricing, industry trends and product and technology initiatives, including products in the development stage, which may not achieve scientific objectives or meet stringent regulatory requirements.
Forward-looking statements are subjects to risks and uncertainties that could cause actual results to differ materially from those contemplated in such forward-looking statements. These statements are based on currently available information and management's current assumptions, expectations and projections about future events. While management believes that its assumption, expectations and projections are reasonable in view of currently available information, you are cautioned to not place undue reliance on these forward-looking statements.
The company's actual results may differ materially from those discussed in this call for a variety of reasons, including those described in the forward-looking statements and Risk Factors sections of the company's Form 10-K for the year ending December 31, 2019, which was filed April 3rd, 2020 and its other filings with the SEC which are available on the Investor relations section of Jaguar's website. Except as required by law, Jaguar Health undertakes no obligation to update or revise any forward-looking statements contained in this presentation to reflect new information, future events or otherwise. Additionally please note, the company's supplement its condensed consolidated financial statements presented on a GAAP basis by providing gross sales, non-GAAP EBITDA and non-GAAP recurring EBITDA.
Jaguar believes that the disclosure items of these non-GAAP measures provide investors with additional information that reflects the basis upon which company management assesses and operates the business. These non-GAAP financial measures should not be viewed in isolation or as substitutes for GAAP net sales and GAAP net loss and are not substitutes for or superior to measures of financial performance in conformity with GAAP. At this time, it's my pleasure to turn the call over to Lisa Conte, Jaguar's Health President and Chief Executive Officer. Lisa, the floor is yours.
Thank you. Thank you all who are on the phone, very much for joining our call today. My name is Lisa Conte. I'm the Founder and CEO of Jaguar Health and are wholly-owned subsidiary Napo Pharmaceuticals, often I'll use Jaguar and Napo interchangeably. I want to start off today's call by giving my heartfelt thanks to our dedicated team, many of whom have been working together with me over the last 30, 31 years with one goal in mind: providing responsibly harvested plant-based medicines to help people and animals live healthier and more vibrant lives. I also would like to give a shout out and happy birthday to our Chief of Staff, Jon Wolin. Mytesi is the first and only natural, fair trade plant-based oral drug approved under FDA botanical guidance.
Our team started in 1989